| dc.contributor.author | Altundag, Kadri | |
| dc.date.accessioned | 2019-12-10T11:20:24Z | |
| dc.date.available | 2019-12-10T11:20:24Z | |
| dc.date.issued | 2017 | |
| dc.identifier.issn | 1083-7159 | |
| dc.identifier.uri | https://doi.org/10.1634/theoncologist.2016-0446 | |
| dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469593/ | |
| dc.identifier.uri | http://hdl.handle.net/11655/15327 | |
| dc.description.abstract | This letter reflects on the PALOMA‐3 study, as related to the safety analysis of premenopausal breast cancer patients. | |
| dc.relation.isversionof | 10.1634/theoncologist.2016-0446 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.title | Safety Analysis Of Premenopausal Breast Cancer Patients In Paloma‐3 Study: Is It Worth Mentioning? | |
| dc.type | info:eu-repo/semantics/article | |
| dc.relation.journal | The Oncologist | |
| dc.contributor.department | İç Hastalıkları | |
| dc.identifier.volume | 22 | |
| dc.identifier.issue | 6 | |
| dc.identifier.startpage | 754 | |
| dc.description.index | PubMed | |
